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Insect cells emerged as a powerful and versatile platform for vaccines production, mostly using the lytic 
baculovirus expression vector system (BEVS). Stable expression in such hosts has been increasingly explored 
to circumvent BEVS-related drawbacks, but protein titers achieved to date are still seemingly low. The design of 
new or improved cell factories and bioprocess intensification strategies are therefore necessary to increase 
productivities and thus accelerate implementation of stable insect cell lines as a fast, cost-effective platform for 
vaccines manufacturing. 
 
In this work, we implemented an innovative site-specific recombination strategy based on flipase-mediated 
cassette exchange technology to establish reusable insect (Sf-9 and High Five) cell platforms for fast production 
of enveloped virus-like particles (VLPs). Influenza M1 and HIV Gag proteins were evaluated as scaffolds, and 
proof-of-concept demonstrated using two membrane proteins: the influenza HA protein (for vaccines) and the 
human beta-2 adrenergic receptor (for drug screening or antibody discovery).  
 
Aiming to improve production yields in developed stable cell lines, two bioprocess engineering schemes were 
evaluated (either individually or in combination): (i) adaptive laboratory evolution of insect cells to hypothermic 
culture conditions, and (ii) supplementation of insect cell cultures with productivity enhancers. The stable cell 
line expressing HIV Gag-VLPs was used as model. Under hypothermic culture conditions, adapted Sf-9 cells 
expressed up to 30-fold more HIV Gag-VLPs than non-adapted cells. Noteworthy, the element driving such 
increase in productivity is the adaptation process and not the temperature shift as the latter alone leads to lower 
production yields. A more modest increase in productivity (up to 7-fold) was observed when supplementing non-
adapted cell cultures with productivity enhancers NaBu and DMSO. No synergistic effect was observed when 
combining adapted cells and supplementation with productivity enhancers. Production of HIV Gag-VLPs was 
successfully scaled-up to stirred-tank bioreactors. 
 
The adapted cell line was then pseudo-typed with influenza HA protein for production of Gag-HA VLPs, and 
their performance benchmarked against (i) parental Sf-9 cells stably expressing Gag-HA VLPs and (ii) insect 
cells-BEVS, both cultured under standard temperature conditions (27C). Adapted cells showed increased 
production of Gag-HA VLPs when compared to parental/stable cells, corroborating previously obtained data, but 
still lower when compared to insect cells-BEVS. Bioprocess intensification strategies are currently under in-
house testing to further improve yields of adapted cells and thus shorten the gap between stable insect cells and 
IC-BEVS. 
 
Overall, the insect cell platforms and bioprocess engineering strategies herein assembled have the potential to 
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